Cập nhật lần cuối :
19/11/2024
Hormon   Vasopressin  
Dạng tiêm
Tính ổn định của các dung dịch Độ ổn định khi trộn lẫn Những yếu tố ảnh hưởng đến độ ổn định Khả năng tương thích Đường dùng Tài liệu tham khảo Pdf

Tên thương mại   Tên thương mại     

Các tên thương mại được cung cấp và thành phần tá dược có thể khác nhau giữa các quốc gia và các hãng dược

Pressyn Canada
Tài liệu tham khảo   Dạng tiêm   Tài liệu tham khảo : Vasopressin  
Loại Nguồn
1057 Tạp chí Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207.
1508 Tạp chí Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
1611 Tạp chí Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506.
1801 Tạp chí Feddema S, Rusho WJ, Tyler LS, Barker B.
Physical compatibility of vasopressin with medications commonly used in cardiac arrest.
Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1902 Tạp chí Walker SE, Wyllie A, Law S.
Physical compatibility of pantoprazole with selected medications during simulated Y-site administration.
Can J Hosp Pharm 2004 ; 57, 2: 90-96.
1963 Tạp chí Honisko ME, Fink JM, Militello MA, Mauro VF, Alexander KS.
Compatibility of argatroban with selected cardiovascular agents.
Am J Health-Syst Pharm 2004 ; 61: 2415-2418.
2017 Tạp chí Barker B, Feddema S, Rusho WJ, Dengg R.
Visual compatibility of vasopressin with other injectable drugs.
Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2108 Tạp chí Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2116 Tạp chí Faria CE, Fiumara K, Patel N, Tran DC.
Visual compatibility of furosemide with phenylephrine and vasopressine.
Am J Health-Syst Pharm 2006 ; 63: 906-908.
2269 Tạp chí Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3210 Tạp chí Jasti Bhaskara R, Saraf Poonam.
Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations.
Int J Pharm Compound 2011 ; 15, 3: 259-261.
3249 Tạp chí Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254 Tạp chí Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3429 Tạp chí Foushee J.A, Fox L.M, Gormley L.R, Lineberger M.S.
Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration
Am J Health-Syst Pharm 2015 ; 72:483-486
3827 Poster Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 Poster Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
4055 Tạp chí Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 Tạp chí Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4389 Tạp chí Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213
4433 Tạp chí Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485.
4434 Tạp chí Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4528 Tạp chí Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4569 Tạp chí Lee T.M , Villareal C.L, Meyer L.M.
Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications.
Hosp Pharm 2021 ; 56, 4: 282-286.
4570 Tạp chí Greenhill K, Hornsby E, Gorman G.
Investigations of Physical Compatibilities of Commonly Used Intravenous Medications with and without Parenteral Nutrition in Pediatric Cardiovascular Intensive Care Unit Patients.
Pharmaceuticals 2019
4655 Tạp chí Holyk A, Lindner A, Lindner S, Shippert B
Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration.
Am J Health-Syst Pharm 2022 ;79,1:27-33
4732 Tạp chí Kenneally A, Agbana P, Gardner B, Bae Y, Mitchell T, Beckman E.
Compatibility of calcium chloride with milrinone, epinephrine, vasopressin, and heparin via in vitro testing and simulated Y-site administration.
Am J Health-Syst Pharm 2023 80, 3;164–170
4801 Tạp chí Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1:
4818 Thông tin của nhà sản xuất Giapreza 2.5mg per ml concentrate for solution for infusion - Summary of Product Characteristics Updated 30-Jun-2022
PAION UK Ltd 2022

  Mentions Légales